Exploratory Studies of Urine and Blood Biomarkers in Nephrotic Syndrome

Overview

About this study

The purpose of this study is to determine whether the source of urinary CD80 and CD163 and other biomarkers elevated in Nephrotic Syndrome is from renal cells or a subset of circulating white blood cells. Also, the study aims to determine whether CD80 and CD163 and other biomarkers levels can predict disease response to treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Patients between the ages of 1 day and 100 years of age.

Exclusion Criteria: 

  1. Individuals unable to provide consent or assent.
  2. Pregnancy women and prisoners will not be asked to participate.
  3. Patient considered unsuitable for enrollment in the opinion of the PI.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marie Hogan, M.D., Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Troy Ofstie R.N., CCRP

(507)255-1087

Ofstie.Troy@mayo.edu

More information

Publications

Publications are currently not available